Drug Action
Follitropin delta is a recombinant human follicle stimulating hormone, which causes development of multiple mature follicles.
PDF page 808
Loading InternPractice…
Drug reference
Follitropin delta is a recombinant human follicle stimulating hormone, which causes development of multiple mature follicles.
PDF page 808
Superovulation treatment for assisted conception (such as in vitro fertilisation) (initiated under specialist supervision) ▶BY SUBCUTANEOUS INJECTION ▶Adult (female): Initial dosing based on serum anti- Müllerian hormone concentration and body-weight— consult product literature.
PDF page 808
Ovarian cysts (not caused by polycystic ovarian syndrome). ovarian enlargement (not caused by polycystic ovarian syndrome). tumours of breast . tumours of hypothalamus. tumours of ovaries. tumours of pituitary. tumours of uterus. vaginal bleeding of unknown cause
PDF page 808
Acute porphyrias p. 1120. history of tubal disease (increased risk of ectopic pregnancy)
PDF page 808
Follitropin delta is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1. l HANDLING AND STORAGE Manufacturer advises store in a refrigerator (2–8 °C)—consult product literature for further information regarding storage conditions outside refrigerator.
PDF page 808
▶Common or very common Fatigue. headache. nausea. ovarian and fallopian tube disorders. pelvic disorders. uterine pain ▶Uncommon Abdominal discomfort. breast abnormalities. constipation. diarrhoea. dizziness. drowsiness. mood swings. vaginal haemorrhage. vomiting ▶Rare or very rare Thromboembolism SIDE-EFFECTS, FURTHER INFORMATION If ovarian hyperstimulation syndrome occurs, the patient should be advised to withhold hCG and avoid intercourse or use barrier contraceptive methods for at least 4 days.
PDF page 808
Manufacturer advises avoid—not indicated during pregnancy.
PDF page 808
Manufacturer advises avoid—not indicated during breastfeeding.
PDF page 808
Manufacturer advises regular monitoring of ovarian response with ultrasound alone, or in combination with serum estradiol levels. Frequent monitoring of follicular development is required to reduce the risk of ovarian hyperstimulation syndrome during treatment, and for at least 2 weeks after triggering of final follicular maturation—consult product literature.
PDF page 808
Manufacturer recommends the cartridge should be used with the Rekovelle ® injection pen. The first injection should be performed under direct medical supervision; self- administration should only be performed by patients who are well motivated, adequately trained and have access to expert advice.
PDF page 808
There can be variation in the licensing of different medicines containing the same drug. Solution for injection A ▶Follitropin delta (non-proprietary) Follitropin delta 33.33 microgram per 1 ml Rekovelle 36micrograms/1.08ml solution for injection pre-filled pens | 1 pre- filled disposable injection P £354.94 Rekovelle 72micrograms/2.16 ml solution for injection pre-filled pens | 1 pre-filled disposable injection P £709.89 Rekovelle 12micrograms/0.36ml solution for injection pre-filled pens | 1 pre-filled disposable injection P £118.31 ▶Rekovelle (Ferring Pharmaceuticals Ltd) A Follitropin delta 33.33 microgram per 1 ml Rekovelle 12micrograms/0.36ml solution for injection cartridges | 1 cartridge P £118.31 Rekovelle 36micrograms/1.08ml solution for injection cartridges | 1 cartridge P £354.94 Rekovelle 72micrograms/2.16ml solution for injection cartridges | 1 cartridge P £709.89
PDF page 809
Conception and contraception Manufacturer advises that patients planning to conceive should be warned that there is a risk of multiple pregnancy.
PDF page 809
Initial dosing based on serum anti-
First-line fragment. Read the complete Indications and Dose section above.
PDF page 808